Exeliom Biosciences

We're developing

Monoclonal Microbial Therapies

as a new class of medicines

(former Nextbiotix)

Our goal is to leverage the central role of the gut microbiota in the immune system.

Our lead program is a monoclonal microbial drug candidate, using a single strain of the bacteria species Faecalibacterium prausnitzii.

This novel treatment aims at offering a complementary strategy to patients and physicians for the treatment of inflammatory bowel diseases, such as Crohn Disease or Ulcerative Colitis.

Our strain was rationally selected for its superior properties.

Faecalibacterium prausnitzii uniquely combines 4 characteristics:

Natural-occurring bacterial species in the human gut flora of all human beings across all geographies
Most abundant bacterial species in the gut microbiota of healthy subjects
Almost absent in patients with inflammatory bowel diseases
Predictive of good health in patients with inflammatory bowel diseases

We have observed in preclinical studies that orally-delivered pharmaceutical compositions of Faecalibacterium prausnitzii can downregulate immune responses and reduce pain.

Our Portfolio

We are working to advance our lead candidate into several clinical studies across inflammatory bowel diseases.

In parallel, we are also leveraging our technological advances and know-how to set-up a state-of-the-art platform specialized in the development of new monoclonal microbial candidates in other therapeutic areas.

Exeliom Biosciences Was Founded by a Pioneer Team in the Field of Translational Microbiome Research

Philippe Langella, PhD

RESEARCH DIRECTOR, INRA

Harry Sokol, MD, PhD

PROF. OF GASTROENTEROLOGY, APHP

Patrick Gervais, PhD

PROF. OF PROCESS ENGINEERING,

AGROSUP DIJON

More about our team

The complementarity between fundamental research and clinical studies has always been the cornerstone of our success

Relevant Publications

CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon
receptor ligands.
Nature medicine - 2016.

Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium
deficient in Crohn’s disease.
Gut - 2016

Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.
BMC Biology - 2015

Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii.
Gut - 2014

The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models.
IBD - 2014

CD4CD8aa Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease.
PLOS Biology - 2014

Faecalibacterium prausnitzii and human intestinal health.
Current Opinion Micr - 2013

Low Counts of Faecalibacterium prausnitzii in Colitis Microbiota.
IBD - 2009

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
PNAS - 2008

En voir plus

News & Press

August 2019 - Exeliom Biosciences is selected as a Deeptech grantee by Bpifrance
July 2018 - Exeliom Biosciences is selected as an i-LAB2018 winner by Bpifrance
June 2018 - Exeliom Biosciences secures €7M Series A round (press release)
October 2017 - Exeliom Biosciences is selected by the Wilco accelerator program
March 2017 - Exeliom Biosciences is selected by the Paris Biotech Santé incubator
December 2016 - Exeliom Biosciences is founded

Contact

HQ Offices

67 rue des Godrans, 21000 Dijon

Paris Offices

24 rue du Faubourg Saint-Jacques, 75014 Paris (Paris Biotech Santé, Cochin)

For general inquiries contact: